SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies

Inclusion Criteria: * Age ≥18 and \<70 years, regardless of gender; * T-ALL/LBL was diagnosed according to the criteria of NCCN Clinical Practice Guidelines for Acute Lymphocytic Leukemia (2020.v1) and T-cell Lymphoma Clinical Practice Guidelines (2020.v1); * Patients diagnosed with AML with reference to the Guidelines for Diagnosis and Treatment of Adult Acute Myeloid Leukemia (2018 Edition) issued by the Health Commission; * Cytology confirmed that the tumor cells were CD7 positive. * Number of blasts in bone marrow ≥5% at screening (bone marrow morphology); * Complies with the diagnosis of relapsed/refractory AML, including any of the following conditions according to China Guidelines for Diagnosis and Treatment of Relapsed/Refractory Acute Myeloid Leukemia (2021 Edition): a. Primary refractory patients who did not achieve CR after two cycles of standard induction chemotherapy; b. CR after consolidation chemotherapy, relapse within 12 months; c. Relapse 12 months after remission but ineffective after conventional chemotherapy; d. 2 or more relapses; e. Relapse after hematopoietic stem cell transplantation. * Meet the diagnosis of relapsed/refractory T-ALL/LBL, including any of the following: a. Primary refractory patients who have not achieved complete response after two cycles of standard chemotherapy, or patients who have not achieved complete response after multi-line rescue chemotherapy; b. Relapse within \<12 months after complete remission or ≥12 months after comple…